查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771611

疫苗市場規模、佔有率、趨勢分析報告：按類型、給藥途徑、適應症、年齡層、分銷管道、地區、細分預測，2025-2033

Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route Of Administration (Oral), By Disease Indication (HPV, MMR), By Age Group (Adult), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

疫苗市場的成長與趨勢：

根據Grand View Research的最新報告，到2033年全球疫苗市場規模預計將達到1,519.6億美元。

預計2025年至2033年期間，該市場將以7.8%的複合年成長率擴張。這一成長主要得益於免疫接種計畫的增加以及針對呼吸道合胞病毒和披衣菌感染等疾病的疫苗的研發。在改善公共衛生關注疾病疫苗的可及性方面已取得重大進展。全球已開發並分發了許多新型疫苗，從而挽救了無數生命，並預防了多種疾病。

此外，疫苗市場中還有多項旨在改善疫苗可近性、開發新型疫苗和確保疫苗安全的舉措。這些舉措涉及國際組織、政府、私人企業和慈善機構。透過合作與創新，這些舉措正在幫助應對全球衛生挑戰並改善公共衛生成果。例如，COVAX是一項旨在確保公平獲得新冠疫苗的全球計劃。該舉措由全球疫苗免疫聯盟（Gavi）、世界衛生組織（WHO）和流行病防範創新聯盟（CEPI）共同主導。

儘管 2021 年有超過 90 家疫苗製造商向世界衛生組織 (WHO) 成員國供應疫苗，但供應仍然嚴重依賴不到 10 家擁有多樣化可部署可用技術和全球影響力的製造商。這種集中導致了區域供應不穩定和市場健康問題，尤其是在非洲和東地中海地區。在美國，預計 COVID 疫苗市場可能在 2023 年下半年私有化。此次私有化可能會提高 COVID 疫苗的價格，並向其他參與者開放市場。例如，Moderna 和輝瑞 BioNTech 都宣布，他們可能會將各自的 mRNA COVID 疫苗的價格提高到每劑約 110-130 美元。

疫苗市場亮點

  • 次單位疫苗將佔2024年疫苗市場的44.30%，預計在預測期內將快速成長。
  • 由於腸外給藥是接種疫苗的首選方法，該部分將在 2024 年佔據疫苗市場的主導地位，佔有率為 96.65%。
  • 病毒性疾病領域將在 2023 年佔據疫苗市場的主導地位，佔有率為 63.79%，主要受 COVID-19 疫苗的推動。
  • 2024年，成人疫苗佔疫苗市場的55.73%。包括新冠疫苗在內的成人疫苗佔全球疫苗總量的75%，而兒童疫苗約佔20%。
  • 2024年，政府供應商佔據疫苗市場的54.81%的佔有率。
  • 預計預測期內北美疫苗市場將以最快的複合年成長率成長。

目錄

第1章調查方法與範圍

第2章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場趨勢與展望
  • 市場動態
    • 疫苗接種在世界各地變得越來越重要
    • 慢性病和感染疾病負擔加重
    • 疫苗研發技術進步
  • 市場限制因素分析
    • 缺乏醫療基礎設施
    • 疫苗接種費用
  • 商業環境分析
    • SWOT分析：按因素（政治/法律、經濟/技術）
    • 波特五力分析
  • COVID-19影響分析

第 3 章 業務分析的類型

  • 2024 年及 2033 年各類型市場佔有率
  • 細分儀表板
  • 疫苗市場：按類型展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 次單位疫苗
    • 次單位疫苗市場（2021-2033）
    • 重組疫苗
    • 結合疫苗
    • 類毒素疫苗
  • 惰性
  • 減毒活疫苗
  • mRNA疫苗
  • 病毒載體疫苗

4. 管理路線業務分析

  • 2024 年和 2033 年按給藥途徑分類的市場佔有率
  • 細分儀表板
  • 疫苗市場：按給藥途徑展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 口服
  • 腸外
  • 鼻腔

第5章 業務指標分析

  • 2024 年及 2033 年各適應症市場佔有率
  • 細分儀表板
  • 疫苗市場：按疾病適應症的展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 病毒性疾病
    • 病毒性疾病疫苗市場，2021-2033年
    • 肝炎
    • 流感
    • HPV
    • MMR
    • 輪狀病毒
    • 帶狀皰疹
    • COVID-19
    • 其他
  • 細菌疫苗
    • 細菌疫苗市場，2021-2033
    • 病菌感染
    • 肺炎鏈球菌感染
    • 兩次口服劑量
    • 其他
  • 癌症疫苗
  • 過敏疫苗

第6章 年齡層業務分析

  • 2024年及2033年各年齡層市場佔有率
  • 細分儀表板
  • 疫苗市場：年齡層展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 孩子們
  • 成人

第7章通路業務分析

  • 2024年及2033年分銷通路市場佔有率
  • 細分儀表板
  • 疫苗市場：分銷通路展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 醫院和藥房
  • 政府供應商
  • 其他

第8章區域業務分析

  • 2024 年及 2033 年各地區疫苗市場佔有率
  • 北美洲
    • 北美疫苗市場（2021-2033）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲疫苗市場（2021-2033）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太疫苗市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲疫苗市場（2021-2033）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲疫苗市場（2021-2033）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 參與企業概況
  • 財務表現
  • 參與企業
    • 市場領導者
    • 2023年疫苗市場佔有率分析
    • 公司簡介
    • 戰略地圖
      • Serum Institute of India Pvt. Ltd.
      • Seqirus
      • Sanofi
      • GSK Plc.
      • Merck & Co., Inc.
      • Pfizer Inc.
      • Moderna Inc.
      • Sinovac
      • BioNTech SE
      • AstraZeneca
Product Code: 978-1-68038-990-6

Vaccine Market Growth & Trends:

The global vaccine market size is expected to reach USD 151.96 billion by 2033, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.8% from 2025 to 2033. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Vaccine Market Report Highlights:

  • The subunit Vaccines segment dominated the vaccine market with a share of 44.30% in 2024 and is expected to experience rapid growth during the forecast period.
  • Parenteral administration is highly preferred for administering vaccines and hence the segment dominated the vaccine market with a share of 96.65% in 2024.
  • The viral diseases segment dominated the vaccine market with a share of 63.79% in 2023, majorly attributed to COVID-19 vaccines.
  • Adult accounted for a share of 55.73% in the vaccine market in 2024. Adult vaccination, including those for COVID-19, comprised 75% in terms of volume globally, while pediatric vaccines accounted for about 20%.
  • Government suppliers dominated the vaccine market in 2024 with a share of 54.81%.
  • North America vaccines market is estimated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Route of Administration
    • 1.2.3. Disease Indication
    • 1.2.4. Age Group
    • 1.2.5. Distribution Channel
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Market Variables, Trends, & Scope

  • 2.1. Market Segmentation and Scope
  • 2.2. Market Lineage Outlook
    • 2.2.1. Parent Market Outlook
    • 2.2.2. Related/Ancillary Market Outlook
  • 2.3. Market Trends and Outlook
  • 2.4. Market Dynamics
    • 2.4.1. Rise in the importance of immunization across the globe
    • 2.4.2. Growing Burden of Chronic and Infectious Diseases
    • 2.4.3. Technology advancements in the vaccination development
  • 2.5. Market Restraint Analysis
    • 2.5.1. Lack of healthcare infrastructure
    • 2.5.2. Cost of immunization
  • 2.6. Business Environment Analysis
    • 2.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 2.6.2. Porter's Five Forces Analysis
  • 2.7. COVID-19 Impact Analysis

Chapter 3. Type Business Analysis

  • 3.1. Type Market Share, 2024 & 2033
  • 3.2. Segment Dashboard
  • 3.3. Vaccines Market by Type Outlook
  • 3.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 3.5. Subunit Vaccines
    • 3.5.1. Vaccine Market for Subunit Vaccines, 2021 - 2033 (USD Billion)
    • 3.5.2. Recombinant vaccines
      • 3.5.2.1. Vaccine Market for Recombinant vaccines, 2021 - 2033 (USD Billion)
    • 3.5.3. Conjugate Vaccines
      • 3.5.3.1. Vaccine Market for Conjugate vaccines, 2021 - 2033 (USD Billion)
    • 3.5.4. Toxoid vaccines
      • 3.5.4.1. Vaccine Market for Toxoid vaccines, 2021 - 2033 (USD Billion)
  • 3.6. Inactivated
    • 3.6.1. Vaccine Market for Inactivated, 2021 - 2033 (USD Billion)
  • 3.7. Live Attenuated
    • 3.7.1. Vaccine Market for Live Attenuated, 2021 - 2033 (USD Billion)
  • 3.8. mRNA vaccines
    • 3.8.1. Vaccine Market for mRNA vaccines, 2021 - 2033 (USD Billion)
  • 3.9. Viral vector vaccines
    • 3.9.1. Vaccine Market for Viral vector vaccines, 2021 - 2033 (USD Billion)

Chapter 4. Route Of Administration Business Analysis

  • 4.1. Route of administration Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Vaccines Market by Route of administration Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Oral
    • 4.5.1. Vaccine Market for Oral, 2021 - 2033 (USD Billion)
  • 4.6. Parenteral
    • 4.6.1. Vaccine Market for Parenteral, 2021 - 2033 (USD Billion)
  • 4.7. Nasal
    • 4.7.1. Vaccine Market for Nasal, 2021 - 2033 (USD Billion)

Chapter 5. Disease Indication Business Analysis

  • 5.1. Disease Indication Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Vaccines Market by Disease Indication Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Viral Diseases
    • 5.5.1. Vaccine Market for Viral Diseases, 2021 - 2033 (USD Billion)
    • 5.5.2. Hepatitis
      • 5.5.2.1. Vaccine Market for Hepatitis, 2021 - 2033 (USD Billion)
    • 5.5.3. Influenza
      • 5.5.3.1. Vaccine Market for Influenza, 2021 - 2033 (USD Billion)
    • 5.5.4. HPV
      • 5.5.4.1. Vaccine Market for HPV, 2021 - 2033 (USD Billion)
    • 5.5.5. MMR
      • 5.5.5.1. Vaccine Market for MMR, 2021 - 2033 (USD Billion)
    • 5.5.6. Rotavirus
      • 5.5.6.1. Vaccine Market for Rotavirus, 2021 - 2033 (USD Billion)
    • 5.5.7. Herpes Zoster
      • 5.5.7.1. Vaccine Market for Herpes Zoster, 2021 - 2033 (USD Billion)
    • 5.5.8. COVID-19
      • 5.5.8.1. Vaccine Market for Covid-19, 2021 - 2033 (USD Billion)
    • 5.5.9. Others
      • 5.5.9.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)
  • 5.6. Bacterial Vaccines
    • 5.6.1. Vaccine Market for Bacterial Vaccines, 2021 - 2033 (USD Billion)
    • 5.6.2. Meningococcal Diseases
      • 5.6.2.1. Vaccine Market for Meningococcal Diseases, 2021 - 2033 (USD Billion)
    • 5.6.3. Pneumococcal Diseases
      • 5.6.3.1. Vaccine Market for Pneumococcal Diseases, 2021 - 2033 (USD Billion)
    • 5.6.4. DPT
      • 5.6.4.1. Vaccine Market for DPT, 2021 - 2033 (USD Billion)
    • 5.6.5. Others
      • 5.6.5.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)
  • 5.7. Cancer Vaccines
    • 5.7.1. Vaccine Market for Cancer Vaccines, 2021 - 2033 (USD Billion)
  • 5.8. Allergy Vaccines
    • 5.8.1. Vaccine Market for Allergy Vaccines, 2021 - 2033 (USD Billion)

Chapter 6. Age Group Business Analysis

  • 6.1. Age Group Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Vaccines Market by Age Group Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Pediatric
    • 6.5.1. Vaccine Market for Pediatric, 2021 - 2033 (USD Billion)
  • 6.6. Adult
    • 6.6.1. Vaccine Market for Adult, 2021 - 2033 (USD Billion)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Vaccines Market by Distribution Channel Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Hospital & Retail Pharmacies
    • 7.5.1. Vaccine Market for Hospital & Retail Pharmacies, 2021 - 2033 (USD Billion)
  • 7.6. Government Suppliers
    • 7.6.1. Vaccine Market for Government Suppliers 2021 - 2033 (USD Billion)
  • 7.7. Others
    • 7.7.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)

Chapter 8. Regional Business Analysis

  • 8.1. Vaccine Market Share By Region, 2024 & 2033
  • 8.2. North America
    • 8.2.1. North America Vaccines Market 2021 - 2033 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Vaccine Market 2021 - 2033 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Vaccine Market 2021 - 2033 (USD Billion)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico Vaccine Market 2021 - 2033 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Vaccines Market 2021 - 2033 (USD Billion)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Vaccine Market 2021 - 2033 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Vaccine Market 2021 - 2033 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Vaccine Market, 2021 - 2033 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Vaccine Market 2021 - 2033 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Vaccine Market 2021 - 2033 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Vaccine Market, 2021 - 2033 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Vaccine Market 2021 - 2033 (USD Billion)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Argentina Vaccine Market 2021 - 2033 (USD Billion)
  • 8.6. MEA
    • 8.6.1. MEA Vaccine Market, 2021 - 2033 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Vaccine Market 2021 - 2033 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Vaccine Market 2021 - 2033 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Vaccine Market 2021 - 2033 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Vaccine Market 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Vaccine Market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Serum Institute of India Pvt. Ltd.
        • 9.3.3.1.1. Company Overview
        • 9.3.3.1.2. Financial Performance
        • 9.3.3.1.3. Product Benchmarking
        • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Seqirus
        • 9.3.3.2.1. Company Overview
        • 9.3.3.2.2. Financial Performance
        • 9.3.3.2.3. Product Benchmarking
        • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Sanofi
        • 9.3.3.3.1. Company Overview
        • 9.3.3.3.2. Financial Performance
        • 9.3.3.3.3. Product Benchmarking
        • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. GSK Plc.
        • 9.3.3.4.1. Company Overview
        • 9.3.3.4.2. Financial Performance
        • 9.3.3.4.3. Product Benchmarking
        • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. Merck & Co., Inc.
        • 9.3.3.5.1. Company Overview
        • 9.3.3.5.2. Financial Performance
        • 9.3.3.5.3. Product Benchmarking
        • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Pfizer Inc.
        • 9.3.3.6.1. Company Overview
        • 9.3.3.6.2. Financial Performance
        • 9.3.3.6.3. Product Benchmarking
        • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Moderna Inc.
        • 9.3.3.7.1. Company Overview
        • 9.3.3.7.2. Financial Performance
        • 9.3.3.7.3. Product Benchmarking
        • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Sinovac
        • 9.3.3.8.1. Company Overview
        • 9.3.3.8.2. Financial Performance
        • 9.3.3.8.3. Product Benchmarking
        • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. BioNTech SE
        • 9.3.3.9.1. Company Overview
        • 9.3.3.9.2. Financial Performance
        • 9.3.3.9.3. Product Benchmarking
        • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. AstraZeneca
        • 9.3.3.10.1. Company Overview
        • 9.3.3.10.2. Financial Performance
        • 9.3.3.10.3. Product Benchmarking
        • 9.3.3.10.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Product/Service Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Vaccine Market, by Region, 2021 - 2033 (USD Billion)
  • Table 4 Global Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 5 Global Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 6 Global Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 7 Global Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 8 Global Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 9 North America Vaccine Market, by Country, 2021 - 2033 (USD Billion)
  • Table 10 North America Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 11 North America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 12 North America Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 13 North America Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 14 North America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 15 U.S. Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 16 U.S. Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 17 U.S. Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 18 U.S. Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 19 U.S. Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 20 Canada Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 21 Canada Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 22 Canada Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 23 Canada Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 24 Canada Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 25 Mexico Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 26 Mexico Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 27 Mexico Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 28 Mexico Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 29 Mexico Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 30 Europe Vaccine Market, by Country, 2021 - 2033 (USD Billion)
  • Table 31 Europe Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 32 Europe Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 33 Europe Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 34 Europe Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 35 Europe Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 36 Germany Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 37 Germany Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 38 Germany Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 39 Germany Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 40 Germany Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 41 UK Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 42 UK Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 43 UK Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 44 UK Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 45 UK Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 46 France Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 47 France Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 48 France Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 49 France Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 50 France Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 51 Italy Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 52 Italy Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 53 Italy Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 54 Italy Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 55 Italy Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 56 Spain Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 57 Spain Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 58 Spain Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 59 Spain Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 60 Spain Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 61 Denmark Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 62 Denmark Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 63 Denmark Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 64 Denmark Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 65 Denmark Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 66 Sweden Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 67 Sweden Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 68 Sweden Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 69 Sweden Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 70 Sweden Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 71 Norway Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 72 Norway Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 73 Norway Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 74 Norway Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 75 Norway Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 76 Asia Pacific Vaccine Market, by Country, 2021 - 2033 (USD Billion)
  • Table 77 Asia Pacific Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 78 Asia Pacific Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 79 Asia Pacific Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 80 Asia Pacific Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 81 Asia Pacific Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 82 China Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 83 China Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 84 China Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 85 China Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 86 China Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 87 Japan Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 88 Japan Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 89 Japan Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 90 Japan Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 91 Japan Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 92 India Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 93 India Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 94 India Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 95 India Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 96 India Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 97 South Korea Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 98 South Korea Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 99 South Korea Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 100 South Korea Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 101 South Korea Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 102 Australia Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 103 Australia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 104 Australia Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 105 Australia Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 106 Australia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 107 Thailand Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 108 Thailand Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 109 Thailand Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 110 Thailand Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 111 Thailand Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 112 Latin America Vaccine Market, by Country, 2021 - 2033 (USD Billion)
  • Table 113 Latin America Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 114 Latin America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 115 Latin America Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 116 Latin America Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 117 Latin America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 118 Brazil Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 119 Brazil Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 120 Brazil Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 121 Brazil Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 122 Brazil Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 123 Argentina Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 124 Argentina Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 125 Argentina Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 126 Argentina Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 127 Argentina Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 128 Middle East & Africa Vaccine Market, by Country, 2021 - 2033 (USD Billion)
  • Table 129 Middle East & Africa Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 130 Middle East & Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 131 Middle East & Africa Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 132 Middle East & Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 133 Middle East & Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 134 South Africa Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 135 South Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 136 South Africa Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 137 South Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 138 South Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 139 Saudi Arabia Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 140 Saudi Arabia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 141 Saudi Arabia Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 142 Saudi Arabia Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 143 Saudi Arabia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 144 UAE Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 145 UAE Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 146 UAE Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 147 UAE Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 148 UAE Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 149 Kuwait Vaccine Market, by Type, 2021 - 2033 (USD Billion)
  • Table 150 Kuwait Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
  • Table 151 Kuwait Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
  • Table 152 Kuwait Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
  • Table 153 Kuwait Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 154 Financial performance
  • Table 155 Key companies undergoing expansions
  • Table 156 Key companies undergoing acquisitions
  • Table 157 Key companies undergoing collaborations
  • Table 158 Key companies launching new products/services
  • Table 159 Key companies undergoing partnerships
  • Table 160 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Vaccine Market Segmentation
  • Fig. 7 Market Snapshot, 2024
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2023
  • Fig. 15 Global Vaccine Market: By Type, Movement Analysis
  • Fig. 16 Global Vaccine Market, for Subunit Vaccines, 2021 - 2033 (USD Billion)
  • Fig. 17 Global Vaccine Market, for Recombinant vaccines, 2021 - 2033 (USD Billion)
  • Fig. 18 Global Vaccine Market, for Conjugate Vaccines, 2021 - 2033 (USD Billion)
  • Fig. 19 Global Vaccine Market, for Toxoid vaccines, 2021 - 2033 (USD Billion)
  • Fig. 20 Global Vaccine Market, for Inactivated, 2021 - 2033 (USD Billion)
  • Fig. 21 Global Vaccine Market, for Live Attenuated2021 - 2033 (USD Billion)
  • Fig. 22 Global Vaccine Market, for mRNA vaccines, 2021 - 2033 (USD Billion)
  • Fig. 23 Global Vaccine Market, for Viral vector vaccines, 2021 - 2033 (USD Billion)
  • Fig. 24 Global Vaccine Market: By Route of Administration, Movement Analysis
  • Fig. 25 Global Vaccine Market, for Oral, 2021 - 2033 (USD Billion)
  • Fig. 26 Global Vaccine Market, for Parenteral, 2021 - 2033 (USD Billion)
  • Fig. 27 Global Vaccine Market, for Nasal2021 - 2033 (USD Billion)
  • Fig. 28 Global Vaccine Market: Disease Indication, Movement Analysis
  • Fig. 29 Global Vaccine Market, for Viral Diseases, 2021 - 2033 (USD Billion)
  • Fig. 30 Global Vaccine Market, for Hepatitis, 2021 - 2033 (USD Billion)
  • Fig. 31 Global Vaccine Market, for Influenza2021 - 2033 (USD Billion)
  • Fig. 32 Global Vaccine Market, for HPV, 2021 - 2033 (USD Billion)
  • Fig. 33 Global Vaccine Market, for MMR, 2021 - 2033 (USD Billion)
  • Fig. 34 Global Vaccine Market, for Rotavirus, 2021 - 2033 (USD Billion)
  • Fig. 35 Global Vaccine Market, for Herpes Zoster, 2021 - 2033 (USD Billion)
  • Fig. 36 Global Vaccine Market, for COVID-19, 2021 - 2033 (USD Billion)
  • Fig. 37 Global Vaccine Market, for Bacterial Vaccines, 2021 - 2033 (USD Billion)
  • Fig. 38 Global Vaccine Market, for Meningococcal Diseases, 2021 - 2033 (USD Billion)
  • Fig. 39 Global Vaccine Market, for Pneumococcal diseases, 2021 - 2033 (USD Billion)
  • Fig. 40 Global Vaccine Market, for DPT, 2021 - 2033 (USD Billion)
  • Fig. 41 Global Vaccine Market, for Others, 2021 - 2033 (USD Billion)
  • Fig. 42 Global Vaccine Market, for Cancer Vaccines, 2021 - 2033 (USD Billion)
  • Fig. 43 Global Vaccine Market, for Allergy Vaccines, 2021 - 2033 (USD Billion)
  • Fig. 44 Global Vaccine Market: Age Group, Movement Analysis
  • Fig. 45 Global Vaccine Market, for Pediatric,2021 - 2033 (USD Billion)
  • Fig. 46 Global Vaccine Market, for Adult ,2021 - 2033 (USD Billion)
  • Fig. 47 Global Vaccine Market: Distribution Channel, Movement Analysis
  • Fig. 48 Global Vaccine Market, for Hospital & Retail Pharmacies,2021 - 2033 (USD Billion)
  • Fig. 49 Global Vaccine Market, for Government Suppliers,2021 - 2033 (USD Billion)
  • Fig. 50 Global Vaccine Market, for Others2021 - 2033 (USD Billion)
  • Fig. 51 Regional Marketplace: Key Takeaways Vaccine Market,
  • Fig. 52 Regional Outlook, 2024 & 2033 Vaccine Market,
  • Fig. 53 Global Vaccine Market: Region Movement Analysis
  • Fig. 54 North America Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 55 U.S. Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 56 Canada Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 57 Europe Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 58 Germany Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 59 UK Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 60 France Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 61 Italy Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 62 Spain Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 63 Denmark Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 64 Sweden Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 65 Norway Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 66 Asia Pacific Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 67 Japan Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 68 China Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 69 India Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 70 Australia Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 71 South Korea Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 72 Thailand Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 73 Latin America Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 74 Brazil Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 75 Mexico Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 76 Argentina Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 77 Middle East and Africa Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 78 South Africa Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 79 Saudi Arabia Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 80 UAE Vaccine Market, 2021 - 2033 (USD Billion)
  • Fig. 81 Kuwait Vaccine Market, 2021 - 2033 (USD Billion)